Phase II Study of S-488410 to Treat Non-small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The investigators identified three cancer-testis antigens, as targets for cancer vaccination
against lung cancer. In this clinical study, the investigators examine using a combination of
three peptides from these three antigens (S-488410) the safety, immunogenicity, and antitumor
effect of vaccine treatment for advanced non-small cell lung cancer patients.
Phase:
Phase 2
Details
Lead Sponsor:
Shiga University
Collaborators:
Fukushima Medical University Shionogi Showa University Tohoku University Tokyo University University of Chicago